|
Name |
8-n-butyryl-neosolaniol
|
Molecular Formula | C23H32O9 | |
IUPAC Name* |
4-[11-acetyloxy-2-(acetyloxymethyl)-10-hydroxy-1,5-dimethylspiro[8-oxatricyclo[7.2.1.02,7]dodec-5-ene-12,2'-oxirane]-4-yl]butanoicacid
|
|
SMILES |
CC(=O)OCC12CC(CCCC(=O)O)C(C)=CC1OC1C(O)C(OC(C)=O)C2(C)C12CO2
|
|
InChI |
InChI=1S/C23H32O9/c1-12-8-16-22(10-29-13(2)24,9-15(12)6-5-7-17(26)27)21(4)19(31-14(3)25)18(28)20(32-16)23(21)11-30-23/h8,15-16,18-20,28H,5-7,9-11H2,1-4H3,(H,26,27)
|
|
InChIKey |
QOJFYVBBDLIRKQ-UHFFFAOYSA-N
|
|
Synonyms |
NA
|
|
CAS | NA | |
PubChem CID | NA | |
ChEMBL ID | NA |
Chemical Classification: |
|
|
---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
---|---|---|---|---|---|---|---|---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
Molecular Weight: | 452.5 | ALogp: | 1.6 |
HBD: | 2 | HBA: | 8 |
Rotatable Bonds: | 7 | Lipinski's rule of five: | Accepted |
Polar Surface Area: | 131.9 | Aromatic Rings: | 4 |
Heavy Atoms: | 32 | QED Weighted: | 0.339 |
Caco-2 Permeability: | -5.654 | MDCK Permeability: | 0.00008620 |
Pgp-inhibitor: | 0.274 | Pgp-substrate: | 0.992 |
Human Intestinal Absorption (HIA): | 0.924 | 20% Bioavailability (F20%): | 0.955 |
30% Bioavailability (F30%): | 0.894 |
Blood-Brain-Barrier Penetration (BBB): | 0.097 | Plasma Protein Binding (PPB): | 51.38% |
Volume Distribution (VD): | 0.433 | Fu: | 53.48% |
CYP1A2-inhibitor: | 0.006 | CYP1A2-substrate: | 0.093 |
CYP2C19-inhibitor: | 0.01 | CYP2C19-substrate: | 0.573 |
CYP2C9-inhibitor: | 0.006 | CYP2C9-substrate: | 0.573 |
CYP2D6-inhibitor: | 0.016 | CYP2D6-substrate: | 0.135 |
CYP3A4-inhibitor: | 0.045 | CYP3A4-substrate: | 0.122 |
Clearance (CL): | 2.041 | Half-life (T1/2): | 0.35 |
hERG Blockers: | 0.003 | Human Hepatotoxicity (H-HT): | 0.152 |
Drug-inuced Liver Injury (DILI): | 0.309 | AMES Toxicity: | 0.03 |
Rat Oral Acute Toxicity: | 0.966 | Maximum Recommended Daily Dose: | 0.042 |
Skin Sensitization: | 0.016 | Carcinogencity: | 0.478 |
Eye Corrosion: | 0.003 | Eye Irritation: | 0.01 |
Respiratory Toxicity: | 0.063 |
Similar NPs | Similar Drugs | ||||||
---|---|---|---|---|---|---|---|
NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
ENC005517 | 0.920 | D0G7KJ | 0.270 | ||||
ENC003086 | 0.736 | D01ZOG | 0.262 | ||||
ENC003580 | 0.733 | D08BDT | 0.261 | ||||
ENC002259 | 0.711 | D0H2MO | 0.257 | ||||
ENC003278 | 0.707 | D0L2UN | 0.254 | ||||
ENC003104 | 0.676 | D09WYX | 0.252 | ||||
ENC001179 | 0.673 | D0X7XG | 0.250 | ||||
ENC005586 | 0.642 | D09SIK | 0.248 | ||||
ENC005587 | 0.462 | D0OL7F | 0.248 | ||||
ENC005782 | 0.317 | D03JSJ | 0.247 |